Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365406 | 0.91 | MAPK14 (0.49) | MAPK14NPC1LMNAMAPTRAB9A | |
| SCHEMBL12365083 | 0.89 | MAPK14 (0.48) | MAPK14NPC1LMNAMAPTRAB9A | |
| SCHEMBL12365328 | 0.89 | MAPK14 (0.44) | MAPK14NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12365312 | 0.88 | MAPK14 (0.48) | MAPK14NPC1LMNAMAPTRAB9A | |
| SCHEMBL12389781 | 0.88 | MAPK14 (0.48) | MAPK14NPC1LMNAMAPTRAB9A | |
| SCHEMBL12365301 | 0.88 | MAPK14 (0.43) | MAPK14LMNAMAPT | |
| SCHEMBL12365372 | 0.88 | MAPK14 (0.43) | MAPK14NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12365331 | 0.88 | MAPK14 (0.43) | MAPK14ALPLMAPTSMN1; SMN2 | |
| SCHEMBL12365271 | 0.87 | MAPK14 (0.46) | MAPK14NPC1LMNAMAPTRAB9A | |
| SCHEMBL12365389 | 0.87 | MAPK14 (0.45) | MAPK14MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | MAPK14 3304/4885ALPL 4376/4885NPC1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.